Skip to content
Menu

Parabilis Medicines, Inc. PBLS

Full chart Compare
Set alert

Price alert · PBLS

All alert types
27.24 USD -0.39 (-1.39%)

As ofNov 20, 2026, 9:46 AM EST

26.50 Day range 27.86
22.66 52-week range 42.49
YTD
-13.80%
1 year
-13.80%

 

No chart data for this range yet.
Market cap
3.41B
Revenue (ttm)
2.26M
EPS (ttm)
-3.62
Shares out
123.68M
Forward P/E
-11.77
YTD return
-13.80%
1-year return
-13.80%
50-day average
30.19
200-day average
31.83
Volume
48.59K
Avg volume
961.61K
Open
27.09
Previous close
27.63
Day's range
26.50 – 27.86
52-week range
22.66 – 42.49
Analysts
Strong Buy
Price target
41.00 (+50.5%)
Earnings date
Feb 11, 2027

Key statistics

Enterprise value
2.74B
Price / sales
1529.73
Price / book
3.40
Total cash
871.62M
Total debt
41.83M
Short % of float
9.05%

Fundamental scorecard

3 of 25 checks passed on PBLS’s reported financials

ValueGrowthProfitabilityHealthDividend

3of 25 checks passed

  • Value 0 of 5
  • Growth No data
  • Profitability No data
  • Financial health 3 of 5
  • Dividend No data

Statements to Sep 30, 2026.

Financials — quick view

All financials
PBLS Revenue — quarterly 2.11M
PBLS Net income — quarterly -44.49M
PBLS EPS — quarterly -0.36

Earnings

PBLS recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 11, 2027Dec 30, 2026-0.45———
Nov 12, 2026Sep 30, 2026-0.36-0.360.000.00%
Aug 13, 2026Jun 30, 2026-0.165-2.32-2.15-1,306.06%
May 19, 2026Mar 31, 2026—-0.72——

Upgrades / downgrades

PBLS analyst upgrades and downgrades
DateFirmActionFromTo
Nov 9, 2026Canaccord Genuityinit—Buy
Oct 22, 2026HC Wainwright & Co.init—Buy
Jul 6, 2026Guggenheiminit—Buy
Jul 6, 2026Leerink Partnersinit—Outperform
Jul 6, 2026B of A Securitiesinit—Buy

About Parabilis Medicines, Inc.

Parabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for disease treatment. The company develops stabilized helical peptide therapeutics through its Helicon discovery platform, targeting proteins that are traditionally considered undruggable. Its pipeline includes functional inhibitors of intracellular protein-protein interactions, targeted protein degraders, and targeted radiopharmaceuticals, with a lead clinical program, FOG-001, that acts as a TCF-blocking beta-catenin inhibitor for cancer treatment. The company integrates artificial intelligence and data science into drug discovery, trial design, and clinical strategy optimization. Parabilis Medicines serves clients in the healthcare and life sciences industries, including clinical research organizations and medical professionals involved in oncology and cancer treatment. The company was founded in 2015 and is based in Cambridge, Massachusetts.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on PBLS — it syncs with the Stock Master app.

Insider holders

PBLS insider holders
InsiderRelationLatest transactionDateShares held
BORISY ALEXISDirectorConversion of Exercise of derivative securityJun 10, 2026105,414
FITZGERALD EDWARD MDirectorConversion of Exercise of derivative securityJun 10, 202614,688
FLYNN JAMES EBeneficial Owner of more than 10% of a Class of SecurityConversion of Exercise of derivative securityJun 10, 20260
LEVY GUY BBeneficial Owner of more than 10% of a Class of SecurityPurchaseJun 10, 20260
RA CAPITAL MANAGEMENT, L.P.Beneficial Owner of more than 10% of a Class of SecurityPurchaseJul 21, 20260
SEBULSKY ALAN MDirectorPurchaseJun 14, 20260

Institution ownership

PBLS institution ownership
Holder% heldSharesValueReported
RA Capital Management, L.P.23.59%29,177,964806.04MSep 29, 2026
FMR, LLC8.79%10,867,584300.22MSep 29, 2026
Arch Venture Management, Llc5.19%6,412,780177.15MSep 29, 2026
venBio Partners LLC4.26%5,266,697145.49MSep 29, 2026
Alphabet Inc.3.98%4,919,498135.90MSep 29, 2026
Nextech Invest, Ltd.3.77%4,663,176128.82MSep 29, 2026

Fund ownership

PBLS fund ownership
Holder% heldSharesValueReported
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund0.91%1,121,00030.97MJun 29, 2026
iShares Trust-iShares Russell 2000 ETF0.83%1,027,32128.38MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund0.65%807,76422.31MJun 29, 2026
Fidelity Select Portfolios-Select Biotechnology Portfolio0.41%507,53314.02MSep 29, 2026
T. Rowe Price Health Sciences Fund, Inc.0.39%486,66913.44MJun 29, 2026
JPMorgan Trust II-JPMorgan Small Cap Growth Fund0.39%480,20913.27MJun 29, 2026